These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 19387707)

  • 21. The Prevalence of Vancomycin-Intermediate Staphylococcus aureus and Heterogeneous VISA Among Methicillin-Resistant Strains Isolated from Pediatric Population in a Turkish University Hospital.
    Mirza HC; Sancak B; Gür D
    Microb Drug Resist; 2015 Oct; 21(5):537-44. PubMed ID: 25919019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus: Does Vancomycin Heteroresistance Matter?
    Claeys KC; Lagnf AM; Hallesy JA; Compton MT; Gravelin AL; Davis SL; Rybak MJ
    Antimicrob Agents Chemother; 2016 Jan; 60(3):1708-16. PubMed ID: 26729497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis.
    Shariati A; Dadashi M; Moghadam MT; van Belkum A; Yaslianifard S; Darban-Sarokhalil D
    Sci Rep; 2020 Jul; 10(1):12689. PubMed ID: 32728110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of vancomycin use trend change due to the availability of alternative antibiotics on the prevalence of Staphylococcus aureus with reduced vancomycin susceptibility: a 14-year retrospective study.
    Kang YR; Kim SH; Chung DR; Ko JH; Huh K; Cho SY; Kang CI; Peck KR
    Antimicrob Resist Infect Control; 2022 Aug; 11(1):101. PubMed ID: 35932086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure.
    Kelley PG; Gao W; Ward PB; Howden BP
    J Antimicrob Chemother; 2011 May; 66(5):1057-60. PubMed ID: 21393156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heart transplantation in a patient with heteroresistant vancomycin-intermediate Staphylococcus aureus ventricular assist device mediastinitis and bacteremia.
    Swartz TH; Huprikar S; Labombardi V; Pinney S; Anyanwu A; Lee M; Patel G
    Transpl Infect Dis; 2013 Oct; 15(5):E177-81. PubMed ID: 23902131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical, microbiological, and genetic characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a teaching hospital.
    Di Gregorio S; Perazzi B; Ordoñez AM; De Gregorio S; Foccoli M; Lasala MB; García S; Vay C; Famiglietti A; Mollerach M
    Microb Drug Resist; 2015 Feb; 21(1):25-34. PubMed ID: 25535825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.
    Howden BP; Davies JK; Johnson PD; Stinear TP; Grayson ML
    Clin Microbiol Rev; 2010 Jan; 23(1):99-139. PubMed ID: 20065327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.
    Hegde SS; Skinner R; Lewis SR; Krause KM; Blais J; Benton BM
    J Antimicrob Chemother; 2010 Apr; 65(4):725-8. PubMed ID: 20139142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the clinical features, bacterial genotypes and outcomes of patients with bacteraemia due to heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-susceptible S. aureus.
    Park KH; Kim ES; Kim HS; Park SJ; Bang KM; Park HJ; Park SY; Moon SM; Chong YP; Kim SH; Lee SO; Choi SH; Jeong JY; Kim MN; Woo JH; Kim YS
    J Antimicrob Chemother; 2012 Aug; 67(8):1843-9. PubMed ID: 22535621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007).
    Rybak MJ; Leonard SN; Rossi KL; Cheung CM; Sader HS; Jones RN
    J Clin Microbiol; 2008 Sep; 46(9):2950-4. PubMed ID: 18632899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia.
    Maor Y; Hagin M; Belausov N; Keller N; Ben-David D; Rahav G
    J Infect Dis; 2009 Mar; 199(5):619-24. PubMed ID: 19199552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus.
    Hafer C; Lin Y; Kornblum J; Lowy FD; Uhlemann AC
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5845-51. PubMed ID: 22948864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center.
    Maor Y; Rahav G; Belausov N; Ben-David D; Smollan G; Keller N
    J Clin Microbiol; 2007 May; 45(5):1511-4. PubMed ID: 17344363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The incidence and risk factors for heterogeneous vancomycin intermediate Staphylococcus aureus].
    Feng NN; Wang Q; Song YL; He LX; Zhou CM; Xie HM; Li HY
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):318-22. PubMed ID: 23925360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates.
    van Hal SJ; Paterson DL
    Antimicrob Agents Chemother; 2011 Jan; 55(1):405-10. PubMed ID: 21078939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protein Biomarker Discovery for Methicillin-Sensitive, Heterogeneous Vancomycin-Intermediate and Vancomycin-Intermediate
    Liu YC; Lu JJ; Lin LC; Lin HC; Chen CJ
    J Proteome Res; 2021 Jan; 20(1):164-171. PubMed ID: 33058664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA.
    Horne KC; Howden BP; Grabsch EA; Graham M; Ward PB; Xie S; Mayall BC; Johnson PD; Grayson ML
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3447-52. PubMed ID: 19506056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center.
    Lin SY; Chen TC; Chen FJ; Chen YH; Lin YI; Siu LK; Lu PL
    J Microbiol Immunol Infect; 2012 Dec; 45(6):435-41. PubMed ID: 22749725
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).
    Appelbaum PC
    Int J Antimicrob Agents; 2007 Nov; 30(5):398-408. PubMed ID: 17888634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.